Bevacizumab biosimilar (Biocad)

贝伐珠单抗生物类似药（Biocad）

Report date: 2022/12/22 13:54:56

Base Information

Drug NameBevacizumab biosimilar (Biocad)
Drug Alias Name贝伐赛珠单抗生物仿制药（Biocad）贝伐人源化单抗生物仿制药 (Biocad)贝伐珠单抗生物仿制药 (Biocad)贝伐单抗生物仿制药 (Biocad)Avegra +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degenerationMacular DegenerationUterine Cervical Neoplasms +[11] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2015/11/25
Country/TerritoryUkraineRussian FederationBelarus +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesSPH-BIOCAD Biopharmaceuticals (SH) Co LtdBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsWet age-related macular degenerationMacular Degeneration

Other Information

ATC CodeL01XC07
Related LinksWikipediaDrugBankKEGG